The conundrum of fluoroquinolone prophylaxis

Nature Clinical Practice Oncology

Volumn 3, Issue 10, 2006, Pages 524-525

  Freifeld, Alison ^a   Sepkowitz, Kent ^b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ACUTE LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG INDICATION; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITALIZATION; HUMAN; INFECTION RISK; LYMPHOMA; MORTALITY; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SOLID TUMOR; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CHEMICALLY INDUCED DISORDER; NEOPLASM; PATIENT SELECTION; STEM CELL TRANSPLANTATION; SURVIVAL;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; FLUOROQUINOLONES; HUMANS; NEOPLASMS; NEUTROPENIA; PATIENT SELECTION; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS;

EID: 33750588172     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0632     Document Type: Review

References (12)

1. Bodey GP et al. (1966) Qantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64: 328-340
2. Karp JE et al. (1987) Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 106: 1-7
3. Lew MA et al (1995) Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: A randomized, controlled trial. J Clin Oncol 13: 239-250
4. Bow EJ et al. (1996) Onolone-based antibacterial chemoprophylaxis in neutropenic patients: Effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Ann Intern Med 125: 183-190
5. Engels EA et al. (1998) Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta-analysis. J Clin Oncol 16: 1179-1187
6. Kern WV et al. (11994) Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 38: 681-687
7. Baum HV et al. (2000) Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients. Infection 28: 278-281
8. Bochud PY et al. (1994) Bacteremia due to viridans streptococci in neutropenic patients: A review. Am J Med 97: 256-264
9. National Comprehensive Cancer Network (2005) Fever and neutropenia: Clinical Practice Guidelines in Oncology - v.1.2006. [http://www.nccn.org/professionals/physiciangls/PDF/fever.pdf] (accessed 23 August 2006)
10. Gafter-Gvili A et al. (2005) Meta-analysis: Antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142: 979-995
11. Bucaneve G et al. (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353: 977-987
12. Cullen M et al. (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353: 988-998